A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy Adults - Trial NCT06393517
Access comprehensive clinical trial information for NCT06393517 through Pure Global AI's free database. This Phase 1 trial is sponsored by Pfizer and is currently Not yet recruiting. The study focuses on Healthy Participants. Target enrollment is 12 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Pfizer
Timeline & Enrollment
Phase 1
Apr 30, 2024
Jul 15, 2024
Primary Outcome
Area Under the Curve from time zero to extrapolated infinite time (AUCinf) of PF-06954522 to evaluate the relative bioavailability of three PF-06954522 formulations administered in the fasted state.,Maximum Observed Plasma Concentration (Cmax) of PF-06954522 to evaluate the relative bioavailability of three PF-06954522 formulations administered in the fasted state.
Summary
The purpose of this study is to compare three finished products of PF-06954522 in terms of
 the uptake into the blood stream.
 
 This study is seeking participants who are:
 
 - Healthy male or female participants aged 18 years or older.
 
 All participants in this study will receive PF-06954522 once by mouth. The participants may
 receive different tablets by mouth for PF-06954522.
 
 The study will compare experiences of people receiving three different products of
 PF-06954522. This will help understand how much PF-06954522 is taken up into the blood for
 each product given.
 
 Participants will take part into the study for about 77 days. During this time participants
 will have to stay onsite for 21 days. There will be one follow up (by telephone) study visit.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06393517
Non-Device Trial